| Literature DB >> 29331943 |
Paulo Gustavo Kotze1, Bo Shen2, Amy Lightner3, Takayuki Yamamoto4, Antonino Spinelli5, Subrata Ghosh6, Remo Panaccione1.
Abstract
Perianal fistulae in patients with Crohn's disease (CD) can be associated with significant morbidity resulting in negative impact on quality of life. The last two decades have seen significant advancements in the management of perianal fistulas in CD, which has evolved into a multidisciplinary approach that includes gastroenterologists, colorectal surgeons, endoscopists and radiologists. Despite the introduction of new medical therapies such as antitumour necrosis factor and novel models of care delivery, the best fistula healing rates reported with combined medical and surgical approaches are approximately 50%. More recently, newer biologics, cell-based therapies as well as novel endoscopic and surgical techniques have been introduced raising new hopes that outcomes can be improved upon. In this review, we describe the modern management and the most recent advances in the management of complex perianal fistulising CD, which will likely impact clinical practice. We will explore optimal use of both older and newer biological agents, as well as new data on cell-based therapies. In addition, new techniques in endoscopic and surgical approaches will be discussed. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: biologics; colorectal surgery; crohn’s disease; perianal fistula; therapeutic endoscopy
Mesh:
Year: 2018 PMID: 29331943 DOI: 10.1136/gutjnl-2017-314918
Source DB: PubMed Journal: Gut ISSN: 0017-5749 Impact factor: 23.059